Physician profile
Thomas Lee Sharp
NPI 1801260393
$10,387.23
in general payments reported to CMS, 2019-2025
38 companies · $1,696 in 2025
The $1,696 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $887 · 2021: $1,271 · 2022: $1,379 · 2023: $2,778 · 2024: $1,704 · 2025: $1,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,177.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,866.36 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $1,133.73 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,097.97 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $1,052.60 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $851.79 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $713.43 | 2019-2025 | |
| Amgen INC. | $479.75 | 2019-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $394.31 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $384.91 | 2020-2025 | Jardiance, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $274.44 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $241.81 | 2020-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $217.64 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $188.38 | 2021-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $185.75 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $176.24 | 2019-2024 | Spravato |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $174.32 | 2019-2022 | |
| Exact Sciences Corporation | $126.36 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $107.33 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.51 | 2025 | Caplyta |
| Abbott Laboratories | $79.06 | 2021-2023 | Freestyle Libre 3 |
| Genentech USA, INC. | $59.44 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.08 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $49.12 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Biohaven Pharmaceutical Holding Company Ltd. | $48.83 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $42.75 | 2021-2025 | Camzyos |
| Phathom Pharmaceuticals, INC. | $39.37 | 2024 | Voquezna |
| Verona Pharma, INC. | $35.74 | 2025 | Ohtuvayre |
| Biohaven Pharmaceuticals, INC. | $29.08 | 2021 | |
| Vanda Pharmaceuticals INC. | $24.80 | 2024 | Hetlioz, Fanapt |
| Bausch Health US, LLC | $24.11 | 2022 | |
| Lundbeck LLC | $22.89 | 2025 | Rexulti |
| Daiichi Sankyo INC. | $21.52 | 2021 | |
| Dexcom, INC. | $19.67 | 2025 | Dexcom G6 Transmitter |
| Sun Pharmaceutical Industries INC. | $18.66 | 2020 | |
| Gilead Sciences, INC. | $18.65 | 2022 | |
| Biogen, INC. | $17.21 | 2023 | Skyclarys |
| Inspire Medical Systems, INC. | $15.31 | 2025 | Inspire |
| Allergan, INC. | $13.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.